Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease.
OBJECTIVE
This study focused on lipoprotein composition and properties in systemic lupus erythematosus (SLE).


METHODS
The size distribution of plasma lipoproteins was studied by nuclear magnetic resonance (NMR). Cholesteryl ester transfer protein (CETP) activity was determined by enzyme-linked immunosorbent assay (ELISA). The affinity of low density lipoprotein (LDL) for proteoglycans was assayed. Twenty-six women (aged 52+/-8.2 years) with SLE and a history of cardiovascular disease (CVD) (SLE cases) were compared with 26 age-matched women with SLE and without CVD (SLE controls) and 26 age-matched population-based control women (controls).


RESULTS
Very low density lipoprotein (VLDL) particles (nmol/L) were more prevalent among SLE cases than SLE controls (0.039) and tended to be more common in SLE cases than in controls (p = 0.073). By contrast, high density lipoprotein (HDL) particles (nmol/L) were more prevalent among controls than SLE cases (p = 0.024) whereas the number of LDL particles (nmol/L) did not differ significantly. Small dense (sd)LDL (nmol/L) were more common in controls and tended to be more common in SLE cases than in SLE controls (p = 0.036 and 0.086, respectively). Small high density lipoproteins (sHDL) (nmol/L) were more prevalent in controls than in SLE controls and SLE cases (p = 0.002 and p<0.001, respectively). VLDL or LDL size (nm) did not differ significantly between groups (data not shown) whereas HDL size (nm) was increased among SLE controls as compared to controls (p = 0.024) and tended to be increased among SLE cases as compared to controls (p = 0.070). The affinity of LDL for proteoglycans or CETP activity did not differ between groups (data not shown).


CONCLUSIONS
sdLDL was not increased and SLE cases and SLE controls had decreased levels of sHDL. VLDL differentiates between SLE cases and SLE controls. The lipid pattern in SLE-related CVD was thus not similar to the pattern seen in diabetes or in CVD in general.
Hua
X
X
Department of Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden. xiang.hua@ki.se
Su
J
J
Svenungsson
E
E
Hurt-Camejo
E
E
Jensen-Urstad
K
K
Angelin
B
B
Båvenholm
P
P
Frostegård
J
J
D002340:Carotid Artery Diseases / Q000000981:diagnostic imaging / Q000453:epidemiology* / Q000378:metabolism*; D002914:Chylomicrons / Q000097:blood; D050171:Dyslipidemias / Q000453:epidemiology* / Q000378:metabolism*; D005260:Female; D006801:Humans; D008049:Lipase / Q000097:blood / Q000737:chemistry; D008074:Lipoproteins / Q000097:blood* / Q000737:chemistry; D008075:Lipoproteins, HDL / Q000097:blood / Q000737:chemistry; D053419:Lipoproteins, IDL / Q000097:blood / Q000737:chemistry; D008077:Lipoproteins, LDL / Q000097:blood / Q000737:chemistry; D008079:Lipoproteins, VLDL / Q000097:blood / Q000737:chemistry; D008180:Lupus Erythematosus, Systemic / Q000453:epidemiology* / Q000378:metabolism*; D008875:Middle Aged; D008970:Molecular Weight; D010316:Particle Size; D015995:Prevalence; D011509:Proteoglycans / Q000378:metabolism; D012307:Risk Factors; D014463:Ultrasonography
D002914:Chylomicrons; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D053419:Lipoproteins, IDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D011509:Proteoglycans; D008049:Lipase